Blog

Former U.S. Ambassador to China, U.S. Secretary of Commerce, and Governor of Washington Gary Locke recently authored an opinion piece in the Minnesota Star Tribune highlighting the importance of two bipartisan bills to Minnesota’s innovation ecosystem. According to Locke, the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act and the Patent Eligibility Restoration

C4IP is recognizing William Shockley, John Bardeen, and Walter Brattain, whose invention of the transistor made modern electronics possible. Shockley, Bardeen, and Brattain met in the 1940s at Bell Laboratories when they were hand-picked to work on developing a transistor, a device for generating and amplifying electrical signals. The trio succeeded after just two years,

Activists affiliated with the Initiative for Medicines, Access & Knowledge (I-MAK) and R Street Institute have propagated false narratives about how patents stifle competition in the drug industry and keep generic drugs from coming to market. These erroneous arguments include the ideas that drug developers ‘game’ the FDA’s Orange Book, that they file unnecessary patents

October was a productive month for C4IP! Here’s a roundup of all that we accomplished over the past month. October Highlights: Spotlighting New Insights on Patent Quality On September 30, the nonprofit, nonpartisan Sunwater Institute released a policy report, “Patent Quality in the United States: Findings and Suggestions for Policymakers.” The report reviewed the U.S.

Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From heart health to household appliances, every aspect of our lives has benefited greatly from IP, as shown by these historical examples from the month of October: 1962: On October 9, Wilson Greatbatch received a

C4IP Co-Chair and former USPTO Director Andrei Iancu recently published an opinion piece in Law360 highlighting the importance of passing the bipartisan RESTORE Patent Rights Act. This bill, introduced by Senators Chris Coons (D-DE) and Tom Cotton (R-AR) and Representatives Nathaniel Moran (R-TX) and Madeleine Dean (D-PA), would reinstate injunctions as the default remedy in

The RESTORE Patent Rights Act, introduced in July by a bipartisan group of senators and representatives, would be a pivotal legislative milestone for promoting innovation, if enacted into law. This bill would reestablish injunctive relief as the default legal remedy for patent infringement, preventing patent infringers from using others’ IP and ultimately facing little more

C4IP is recognizing Shuji Nakamura, who enabled modern-day electronics with his invention of the blue LED. Nakamura was born in 1954 in Ehime, Japan, and was working as a scientist for Japanese company Nichia Chemical when he became intrigued by light-emitting diodes (LEDs), which at the time could only emit red or green light and

C4IP Co-Chairs and former USPTO Directors Andrei Iancu and David Kappos recently published an opinion piece in RealClear Health highlighting the unintended consequences that would arise if the Medication Affordability and Patent Integrity Act (MAPIA) is passed by Congress and signed into law. Supporters of the bill argue that drug companies take advantage of a

September was a productive month for C4IP! Here’s a roundup of all that we accomplished over the past month. September Highlights: Advancing the Patent Eligibility Restoration Act The Patent Eligibility Restoration Act (PERA) remains one of the most important innovation policy reforms on the legislative agenda. This bill would promote research and investment in high-tech

Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From clothing to cleaning, every aspect of our lives has benefited greatly from IP, as shown by these historical examples from the month of September: 1938: On September 20, Wallace Carothers received a patent for

The Medication Affordability and Patent Integrity Act, introduced by Senators Maggie Hassan (D-NH) and Mike Braun (R-IN), would require life sciences innovators to share volumes of unnecessary and confidential information related to drug approval with the USPTO. Under the bill, firms would also have to provide lengthy certifications stating that all information submitted to the